BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30556125)

  • 41. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
    Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
    Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
    [No Abstract]   [Full Text] [Related]  

  • 42. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
    Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1.
    Wang P; Chen L; Zhang J; Chen H; Fan J; Wang K; Luo J; Chen Z; Meng Z; Liu L
    Oncogene; 2014 Jan; 33(4):514-24. PubMed ID: 23334332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs.
    Ueda H; Akiyama Y; Shimada S; Mogushi K; Serizawa M; Matsumura S; Mitsunori Y; Aihara A; Ban D; Ochiai T; Kudo A; Tanabe M; Tanaka S
    Endocr Relat Cancer; 2018 Jun; 25(6):619-631. PubMed ID: 29599123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.
    Lastraioli E; Perrone G; Sette A; Fiore A; Crociani O; Manoli S; D'Amico M; Masselli M; Iorio J; Callea M; Borzomati D; Nappo G; Bartolozzi F; Santini D; Bencini L; Farsi M; Boni L; Di Costanzo F; Schwab A; Onetti Muda A; Coppola R; Arcangeli A
    Br J Cancer; 2015 Mar; 112(6):1076-87. PubMed ID: 25719829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition.
    Huang MH; Chou YW; Li MH; Shih TE; Lin SZ; Chuang HM; Chiou TW; Su HL; Harn HJ
    Pharmacol Res; 2019 Jan; 139():50-61. PubMed ID: 30385365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686.
    Wu BH; Chen H; Cai CM; Fang JZ; Wu CC; Huang LY; Wang L; Han ZG
    Oncotarget; 2016 Feb; 7(6):6847-63. PubMed ID: 26760772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suppression of Extracellular Vesicle VEGF-C-mediated Lymphangiogenesis and Pancreatic Cancer Early Dissemination By a Selective HDAC1/2 Inhibitor.
    Wang CA; Li CF; Huang RC; Li YH; Liou JP; Tsai SJ
    Mol Cancer Ther; 2021 Sep; 20(9):1550-1560. PubMed ID: 34210825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.
    Licht JD
    Trans Am Clin Climatol Assoc; 2018; 129():24-36. PubMed ID: 30166694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
    Lee SW; Park DY; Kim MY; Kang C
    Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade.
    Romero OA; Vilarrubi A; Alburquerque-Bejar JJ; Gomez A; Andrades A; Trastulli D; Pros E; Setien F; Verdura S; Farré L; Martín-Tejera JF; Llabata P; Oaknin A; Saigi M; Piulats JM; Matias-Guiu X; Medina PP; Vidal A; Villanueva A; Sanchez-Cespedes M
    Nat Commun; 2021 Jul; 12(1):4319. PubMed ID: 34262032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
    Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
    Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
    Tzatsos A; Paskaleva P; Ferrari F; Deshpande V; Stoykova S; Contino G; Wong KK; Lan F; Trojer P; Park PJ; Bardeesy N
    J Clin Invest; 2013 Feb; 123(2):727-39. PubMed ID: 23321669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
    Hessmann E; Johnsen SA; Siveke JT; Ellenrieder V
    Gut; 2017 Jan; 66(1):168-179. PubMed ID: 27811314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sex-biased and parental allele-specific gene regulation by KDM6A.
    Ma W; Fang H; Pease N; Filippova GN; Disteche CM; Berletch JB
    Biol Sex Differ; 2022 Jul; 13(1):40. PubMed ID: 35871105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b.
    Kugel S; Sebastián C; Fitamant J; Ross KN; Saha SK; Jain E; Gladden A; Arora KS; Kato Y; Rivera MN; Ramaswamy S; Sadreyev RI; Goren A; Deshpande V; Bardeesy N; Mostoslavsky R
    Cell; 2016 Jun; 165(6):1401-1415. PubMed ID: 27180906
    [TBL] [Abstract][Full Text] [Related]  

  • 58. H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma.
    Ávila-López PA; Guerrero G; Nuñez-Martínez HN; Peralta-Alvarez CA; Hernández-Montes G; Álvarez-Hilario LG; Herrera-Goepfert R; Albores-Saavedra J; Villegas-Sepúlveda N; Cedillo-Barrón L; Montes-Gómez AE; Vargas M; Schnoor M; Recillas-Targa F; Hernández-Rivas R
    Oncogene; 2021 Mar; 40(11):2065-2080. PubMed ID: 33627784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.